1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
21st Century Cures Act: Regenerative Medicine Initiative - Research Projects is sponsored by Department of Health And Human Services. The Regenerative Medicine Innovation Project (RMIP) was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA).
Regenerative medicine is an emerging area of science that holds great promise for treating and even curing a variety of injuries and diseases. Regenerative medicine includes using stem cells and other technologies—such as engineered biomaterials and gene editing—to repair or replace damaged cells, tissues, or organs. Stem cell-based approaches are under development in labs around the world, and some have already moved into clinical trials. Such progress notwithstanding, much work remains to be done toward the development of safe and effective regenerative medicine products and to realize the full potential of this field. This listing is currently active. Program number: 93.CRP. Last updated on 2026-01-28.
Get alerted about grants like this
Get emailed when new opportunities from “Department of Health And Human Services” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Cortical neurons derived from iPS cells: Red: neuronal marker TUJ1 (beta III tubulin). Green: cortical marker CUX-1. Blue: nuclear marker DAPI.
The Regenerative Medicine Innovation Project (RMIP) was established by the21 st Century Cures Actto accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA).
Regenerative medicine is an emerging area of science that holds great promise for treating and even curing a variety of injuries and diseases. Regenerative medicine includes using stem cells and other technologies—such as engineered biomaterials and gene editing—to repair or replace damaged cells, tissues, or organs.
Stem cell-based approaches are under development in labs around the world, and some have already moved into clinical trials. Such progress notwithstanding, much work remains to be done toward the development of safe and effective regenerative medicine products and to realize the full potential of this field.
The RMIP is one of four Innovation Projects authorized under theCures Act; the others are the Precision Medicine Initiative (“All of Us”), the Beau Biden Cancer Moonshot, and the BRAIN Initiative. The NIH RMIP launched following passage of the 21 st Century Cures Act, which authorized $30 million over four years “for clinical research to further the field of regenerative medicine using adult stem cells.
” NIH continues to work in close collaboration with the U.S.Food and Drug Administrationto implement the RMIP. Two scientists observe ocular tissue samples under a laser scanning microscope.
#### **Regenerative Medicine Innovation Catalyst (RMIC)** A new resource funded by NIH is being established to more efficiently bring safe and effective adult stem cell-based therapies into clinical trials and to help further the field of regenerative medicine.
The**NIH-funded Regenerative Medicine Innovation Catalyst (RMIC)**has been established to conduct in-depth characterization of the source stem cell and stem cell-derived products to be administered to research subjects, as well as provide storage and dissemination services for in-depth cell characterization results and clinical data.
Researchers funded through the RMIP are expected to provide representative samples of the source stem cells and clinical-grade stem cell product for in-depth characterization through an NIH-designated in-depth cell characterization platform provider.
Information from in-depth cell characterization will promote understanding of whether and how certain cell characteristics contribute to successful clinical outcomes and help inform future product manufacturing. #### **Funded Projects: Advancing the Field of Regenerative Medicine** Almost immediately after the passage of the 21st Century Cures Act, the NIH began working to implement the RMIP.
* During the first year of funding, NIH worked closely with FDA to create awareness of the RMIP, to solicit research proposals, and to make eight competitive supplement awards that leveraged existing research grants.
These clinical research awards cover a broad spectrum of science and new technologies, and have the potential to advance understanding and treatment of common diseases – including diabetes, anemia, corneal and other eye diseases, and chronic skin ulcers – as well as rare diseases, including idiopathic pulmonary fibrosis, inherited skin diseases, and sickle cell disease.
* To help inform future RMIP activities, NIH and FDA hosted a workshop in December 2017 to explore the state of regenerative medicine science involving adult stem cells, with a focus on promising approaches for the development of safe and effective products, scientific areas poised for major transformative advances, and critical gaps that must be addressed to enable significant innovation and rapid advancement of the field.
* Subsequently, that year, the**NIH and FDA worked together to begin developing**core resources and infrastructure to overcome challenges in the regenerative medical field.
According to the current listing, eligibility includes: The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that applies and receives a grant for support of research by a named principal investigator. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. Eligible applicant types include: Unrestricted by Entity Type. Confirm the full requirements in the official notice before applying.
The current listing shows recent federal obligations suggest $6,144,154 (2026). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Yes — 21st Century Cures Act: Regenerative Medicine Initiative - Research Projects is offered by Department of Health And Human Services and this listing comes from SAM.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Elevance Health Foundation's FY2026 Maternal/Infant Health cycle offers grants around $1 million (1–3 years, 15% indirects) to reduce pre-term birth and severe maternal morbidity. But eligibility hinges on a specific 501(c)(3) subsection test, funding concentrates in 10 states plus national scalable programs, and a corporate payer-funder judges you on measurable outcomes, not need. Here is how to read this RFP and compete before the July 31 deadline.
Read articleElevance Health Foundation's maternal/infant health RFP closes July 31, 2026, part of a five-year, $150 million commitment. Last cycle it awarded 29 grants totaling $6.5M across the pregnancy continuum. Here is what the funder actually rewards — measurable disparity reduction, a 15% indirect-cost cap, and scalable models — plus how nonprofits in the 10 priority states should frame a competitive proposal.
Read article